Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
COVID-19
Elderly
Immunomodulatory drugs
Itolizumab
SARS-CoV-2
Journal
Gerontology
ISSN: 1423-0003
Titre abrégé: Gerontology
Pays: Switzerland
ID NLM: 7601655
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
07
2020
accepted:
10
10
2020
pubmed:
27
10
2020
medline:
29
12
2020
entrez:
26
10
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020. Elderly individuals with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS-CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which 19 elderly residents tested positive for SARS-CoV-2. Based on the increased susceptibility to cytokine release syndrome, inducing respiratory and systemic complications in this population, 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody. All patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable, and 18 of the 19 patients (94.7%) were discharged clinically recovered with negative real-time reverse transcription polymerase chain reaction test results at 13 days. After one dose of itolizumab, circulating IL-6 decreased within the first 24-48 h in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminarily assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients that did not receive immunomodulatory therapy. The control subjects were well matched regarding age, comorbidities, and severity of the disease. The percentage of itolizumab-treated, moderately ill patients who needed to be admitted to the intensive care unit was only one-third of that of the control group not treated with itolizumab. Additionally, treatment with itolizumab reduced the risk of death 10 times as compared with the control group. This study corroborates that the timely use of itolizumab in combination with other antivirals reduces COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19. Our results suggest the possible use of itolizumab in patients with cytokine release syndrome from other pathologies.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020. Elderly individuals with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS-CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which 19 elderly residents tested positive for SARS-CoV-2.
METHODS
Based on the increased susceptibility to cytokine release syndrome, inducing respiratory and systemic complications in this population, 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody.
RESULTS
All patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable, and 18 of the 19 patients (94.7%) were discharged clinically recovered with negative real-time reverse transcription polymerase chain reaction test results at 13 days. After one dose of itolizumab, circulating IL-6 decreased within the first 24-48 h in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminarily assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients that did not receive immunomodulatory therapy. The control subjects were well matched regarding age, comorbidities, and severity of the disease. The percentage of itolizumab-treated, moderately ill patients who needed to be admitted to the intensive care unit was only one-third of that of the control group not treated with itolizumab. Additionally, treatment with itolizumab reduced the risk of death 10 times as compared with the control group.
CONCLUSION
This study corroborates that the timely use of itolizumab in combination with other antivirals reduces COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19. Our results suggest the possible use of itolizumab in patients with cytokine release syndrome from other pathologies.
Identifiants
pubmed: 33105142
pii: 000512210
doi: 10.1159/000512210
pmc: PMC7649683
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
itolizumab
XQQ2RHV14N
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-561Informations de copyright
© 2020 S. Karger AG, Basel.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Gerontology. 2020;66(6):553-561
pubmed: 33105142
Adv Nutr. 2020 Sep 25;:
pubmed: 32975565
J Am Acad Dermatol. 2014 Sep;71(3):484-92
pubmed: 24703722
Aging Clin Exp Res. 2020 Aug;32(8):1599-1608
pubmed: 32557332
Hybridoma (Larchmt). 2008 Aug;27(4):291-301
pubmed: 18707547
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Clin Exp Immunol. 2010 Oct;162(1):116-30
pubmed: 20726988
Int J Infect Dis. 2020 Nov;100:421-424
pubmed: 32768701
J Immunother Cancer. 2020 May;8(1):
pubmed: 32385146
PLoS One. 2020 Aug 21;15(8):e0238160
pubmed: 32822430
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Front Immunol. 2018 Jan 10;8:1960
pubmed: 29375577
Results Immunol. 2012 Nov 21;2:204-11
pubmed: 24371585
Mediators Inflamm. 1998;7(5):347-53
pubmed: 9883970
Clin Infect Dis. 2020 Aug 12;:
pubmed: 32785710
Arch Gerontol Geriatr. 2007 Jul-Aug;45(1):65-71
pubmed: 17303263
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632